In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive regulatory approval, raise new funding, unveil new research, and much more on the road to LSI USA ‘25 in Dana Point, CA (March 17-21).
Announced the closing of €180M oversubscribed Sabadell Asabys Health Innovation Investments II (SAHII II) Fund, exceeding its initial target by €30M. SAHII II will invest in 12 to 15 companies within the biopharma, medical device, and digital health space.
Secured approval from Health Canada for its CardioFlux magnetocardiograph for use by physicians to aid in diagnosing myocardial ischemia. CardioFlux is a 90-second, zero-contact scan that assesses cardiac function by examining magnetic fields produced by the heart’s electrical activity without radiation or injections.
Unveiled its suite of second-generation modules for its LapAR, a laparoscopic simulator that integrates AR to deliver high-fidelity surgical training. The new modules offer enhanced haptic feedback, anatomical realism, usability, and scalability.
Closed a $73M Series B funding round led by Threshold Ventures. The funds will be used to support the company’s efforts to scale the use of robotics and AI across mainstream medical procedures.
Obtained the ISO 13485 certification through The British Standards Institution. The company is developing P3D Bone, a new generation of patient-specific, bio-integrative orthopedic implant solutions.
Received a $2M grant from the National Institute of Diabetes and Digestive and Kidney Diseases. The grant will be used to conduct a clinical trial and pursue regulatory clearance for EchoGuide, its newest technology designed to improve cannulation for dialysis patients.
Appointed Alexei Mlodinow as a Venture Partner. SPRIG Equity™ is a medtech growth equity and late-stage venture capital firm. Mlodinow will play a key role in enhancing the company’s investment strategy and supporting its portfolio companies.
Successfully implanted its NAO.VNS™ system, a neural stimulator, in the first two patients as part of the AURORA study. The study aims to evaluate the safety of the NAO.VNS™ system for patients with drug-resistant epilepsy.
Presented research on AI and deep learning innovations in ventricular tachycardia analysis. The two studies analyze the use of Vektor’s vMAPⓇ and associated AI-based techniques to assess wall thickness and scar tissue in ventricular tachycardia patients.
Won first place in the Healthcare Businesswomen’s Association Pitch Competition. Vessl is developing a prosthetic socket that automatically adjusts to redistribute pressure around the leg in response to a change in limb size.
Appointed LSI Alumni Andy McGibbon as its new U.S. Head of Strategy. In this role, McGibbons will concentrate on building the company’s U.S. presence, obtaining strategic partnerships, and driving early commercial activities.
Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.
Schedule an exploratory call
Request Info© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
.png)
